[January 03, 2014]

Research and Markets: Benlysta (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/lwhc68/benlysta) has announced the addition of the "Benlysta (Systemic Lupus Erythematosus and Lupus Nephritis) - Forecast and Market Analysis to 2022" report to their offering.

Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE.

Benlysta is indicated as an add-on therapy in adult patients with active, autoantibody-positive SLE with a high degre of disease activity (such as positive anti-dsDNA and low complement) despite standard therapy. It is a human IgG1 monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS, also referred to as BAFF and TNFSF13B).

Scope

- Overview of SLE-LN, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Benlysta including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Benlysta for the top seven countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for SLE-LN

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Benlysta performance

- Obtain sales forecast for Benlysta from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Key Topics Covered:

1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Benlysta (belimumab)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/lwhc68/benlysta

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

[ Back To TMCnet.com's Homepage ]